Advancing a novel product pipeline of neurology therapies
View Product PipelineAbout
We are a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders.
Our novel product pipeline addresses areas of high unmet medical need, with a focus on epilepsy.
Read MoreNews
Xenon Pharmaceuticals to Present at the Stifel 2023 CNS Days
March 22, 2023
Xenon Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
March 1, 2023
Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update
February 22, 2023
Xenon Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference
February 8, 2023
Xenon Pharmaceuticals Outlines Key Milestone Opportunities for 2023
January 9, 2023
Product Pipeline
XEN1101
for Focal Onset Seizures (FOS)
X-TOLE2/3 Clinical Trial
XEN1101
for Primary Generalized Tonic-Clonic Seizures (PGTCS)
X-ACKT Clinical Trial
XEN1101
for Major Depressive Disorder (MDD)
X-NOVA Clinical trial
XEN1101
for MDD
Investigator-led Phase 2 POC study Collaboration with Mount Sinai
XEN496
for Orphan Pediatric Epilepsy (KCNQ2-DEE)
EPIK Clinical Trial
NBI-921352
for Rare Pediatric Epilepsy: SCN8A-DEE
Partnered with Neurocrine Biosciences
NBI-921352
for Focal-Onset Seizures in Adults
Partnered with Neurocrine Biosciences
Investors
Visit our Investor page for News Releases, Annual & Quarterly Reports, Webcasts & Events
View Investor Area
